PD-L1 negative

Immunotherapy showed substantial benefits in improving pCR rates in both TNBC and HR+HER2- patients when combined with neoadjuvant chemotherapy, especially in lymph node-positive breast cancer patients.

Our findings support previous reports on the immune-privileged status of BCC. Contrary to the literature, we could not confirm PD-L1 expression on BCC cells, but rather on the intra- and peritumoral immune cells. Given these results and the literature suggesting a tendency of higher immunoreactivity compared to other BCC subtypes, basosquamous BCC might be a better target for anti-PD-1 therapy as opposed to other subtypes.

Toripalimab combined with cetuximab demonstrated manageable safety and promising efficacy for R/M HNSCC, warranting further investigation. Clinical trial number: NCT04856631.

Our results suggest that for PD-L1-positive non-squamous cases, the added benefit of extended adjuvant therapy may be limited. However, given our reliance on aggregate data and trial-level imbalances, these findings remain hypothesis-generating and should not alter current clinical practice. Rather, they offer an exploratory framework to inform patient selection for future de-escalation trials.

Guided by precision oncology targeting both immunogenic profile and cell-cycle dysregulation, the patient was treated with dual immunotherapy (pembrolizumab plus ipilimumab) combined with the CDK4/6 inhibitor palbociclib. To our knowledge, this is the first report demonstrating the efficacy of dual checkpoint blockade plus CDK4/6 inhibition in SMARCA4-UT. This case highlights potential of biomarker-driven therapies to overcome resistance in rare thoracic neoplasms.

The addition of hyperthermia to PD-1 inhibitor and chemotherapy significantly improves PFS and reduces specific adverse events in patients with PD-L1 CPS-negative advanced GC. This distinct CTC dynamic change, although still requiring further verification, may offer a potential mechanistic insight into the significant efficacy of this combined strategy.

In our patient, immune checkpoint inhibitors combined with chemotherapy and multi-target inhibitor therapy provided periods of disease stabilization, highlighting the potential role of immunotherapy as part of a multimodal treatment strategy. Comprehensive molecular profiling, including assessment of MTAP status, may further inform future therapeutic options in this rare malignancy.

Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.

Adding ICIs in PD-L1-positive patients improves progression-free survival, with greater clinical benefit observed at higher PD-L1 expression levels. Within the immunotherapy cohort, PD-L1-high patients show a trend toward more pronounced benefit from ICIs.

No statistically significant difference was observed (P=0.65). This study did not find evidence that baseline PD-L1 expression significantly influences the efficacy of entrectinib in advanced ROS1-rearranged NSCLC patients.

In first-line treatment of advanced ovarian cancer, immunotherapy ± PARPi does not provide PFS benefits in unselected patients. However, efficacy signals in specific subgroups support the need for biomarker-driven strategies and optimized trials.

Integration of cytology, immunophenotype, genomics, and treatment delineates distinct prognostic subsets in LUAD with MSE. The absence of actionable driver alterations and TTF-1 negativity remains an independent adverse prognostic factor, with dual TTF-1/PD-L1-negative MSE showing particularly poor SME and OS.